Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM

Prof Thierry Facon - Chu De Lille, Lille, France
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM ( Prof Thierry Facon - Chu De Lille, Lille, France )
25 Jun 2021

The clinical value of maintenance in multiple myeloma

Prof Wee Joo Chng - National University of Singapore, Singapore
The clinical value of maintenance in multiple myeloma ( Prof Wee Joo Chng  - National University of Singapore, Singapore )
25 Jun 2021

Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients

Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA
Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients ( Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA )
25 Jun 2021

Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
25 Jun 2021

Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients

Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho
Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients ( Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho )
22 Jun 2021

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
22 Jun 2021

JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (BSC) versus BSC alone for advanced UC

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (BSC) versus BSC alone for advanced UC ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
22 Jun 2021

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma

Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )
22 Jun 2021

Advances in lung cancer and current situation in Romania

Dr Serban Negru - University of Medicine and Pharmacy Victor Babes Timisoara, OncoHelp Cancer Center
Advances in lung cancer and current situation in Romania ( Dr Serban Negru - University of Medicine and Pharmacy Victor Babes Timisoara, OncoHelp Cancer Center )
21 Jun 2021

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia

Dr John Byrd - The Ohio State University, Columbus, USA
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University, Columbus, USA )
21 Jun 2021

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia

Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA
Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )
17 Jun 2021

EHA 2021: Latest in immunotherapy for R/R multiple myeloma

Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo
EHA 2021: Latest in immunotherapy for R/R multiple myeloma ( Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo )
17 Jun 2021